Renaissance Technologies
ABMD

Renaissance Technologies’s Abiomed Inc ABMD Stock Holding History

Renaissance Technologies’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,265,800
Closed -$311M – 4545
2022
Q3 		$311M Sell
1,265,800
-180,723
-12% -$48.8M 0.44% 32
2022
Q2 		$358M Buy
1,446,523
+32,323
+2% +$8.72M 0.42% 40
2022
Q1 		$468M Sell
1,414,200
-37,100
-3% -$11.4M 0.55% 24
2021
Q4 		$521M Sell
1,451,300
-112,423
-7% -$38M 0.65% 20
2021
Q3 		$509M Sell
1,563,723
-115,200
-7% -$39M 0.66% 21
2021
Q2 		$524M Sell
1,678,923
-101,200
-6% -$31M 0.65% 19
2021
Q1 		$567M Sell
1,780,123
-213,677
-11% -$68.4M 0.71% 13
2020
Q4 		$646M Sell
1,993,800
-263,323
-12% -$72.8M 0.7% 19
2020
Q3 		$625M Buy
2,257,123
+7,001
+0.3% +$2.02M 0.62% 21
2020
Q2 		$544M Buy
2,250,122
+202,122
+10% +$40.6M 0.47% 36
2020
Q1 		$297M Sell
2,048,000
-275,023
-12% -$45.7M 0.29% 71
2019
Q4 		$396M Buy
2,323,023
+187,300
+9% +$34.7M 0.3% 57
2019
Q3 		$380M Sell
2,135,723
-296,000
-12% -$64M 0.32% 53
2019
Q2 		$633M Buy
2,431,723
+370,800
+18% +$98.4M 0.56% 17
2019
Q1 		$589M Buy
2,060,923
+191,200
+10% +$63.5M 0.54% 17
2018
Q4 		$608M Buy
1,869,723
+150,700
+9% +$52.3M 0.67% 13
2018
Q3 		$773M Buy
1,719,023
+167,600
+11% +$66.1M 0.79% 10
2018
Q2 		$635M Buy
1,551,423
+401,800
+35% +$146M 0.69% 12
2018
Q1 		$335M Buy
1,149,623
+66,900
+6% +$17M 0.37% 34
2017
Q4 		$203M Sell
1,082,723
-5,701
-0.5% -$1.06M 0.22% 71
2017
Q3 		$184M Buy
1,088,424
+195,201
+22% +$29.5M 0.22% 80
2017
Q2 		$128M Buy
893,223
+224,523
+34% +$30.2M 0.16% 121
2017
Q1 		$83.7M Buy
668,700
+144,800
+28% +$16.8M 0.12% 198
2016
Q4 		$59M Sell
523,900
-136,323
-21% -$15.8M 0.09% 262
2016
Q3 		$84.9M Buy
660,223
+38,500
+6% +$4.61M 0.15% 135
2016
Q2 		$67.9M Buy
621,723
+334,623
+117% +$33.3M 0.13% 155
2016
Q1 		$27.2M Buy
287,100
+173,400
+153% +$14.6M 0.05% 488
2015
Q4 		$10.3M Sell
113,700
-250,023
-69% -$21.2M 0.02% 969
2015
Q3 		$33.7M Sell
363,723
-86,750
-19% -$7.64M 0.08% 298
2015
Q2 		$29.6M Buy
450,473
+262,210
+139% +$17.4M 0.07% 354
2015
Q1 		$13.5M Buy
+188,263
New +$10.2M 0.03% 783
2014
Q3 		– Sell
-97,223
Closed -$2.44M – 3004
2014
Q2 		$2.44M Buy
+97,223
New +$2.26M 0.01% 1625
2014
Q1 		– Sell
-79,323
Closed -$2.12M – 3072
2013
Q4 		$2.12M Sell
79,323
-181,200
-70% -$4.48M 0.01% 1720
2013
Q3 		$4.97M Buy
260,523
+128,300
+97% +$2.93M 0.01% 1164
2013
Q2 		$2.85M Buy
+132,223
New +$2.66M 0.01% 1392

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Renaissance Technologies's ABMD Position: Q4 2022 in Review

Renaissance Technologies sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 1,265,800 shares — an estimated $311M sold.

Renaissance Technologies first reported a position in ABMD in Q2 2013 and held it in 35 quarters. The position peaked at $773M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Renaissance Technologies reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Renaissance Technologies sold 1,265,800 Abiomed Inc shares in Q4 2022, an estimated $311M.
  • Renaissance Technologies first reported a position in Abiomed Inc in Q2 2013 and held it in 35 quarters.
  • Renaissance Technologies's Abiomed Inc position peaked at $773M in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.